Seed (Seed Health, Inc.)

Seed (Seed Health, Inc.) is a microbiome science and consumer health company that develops clinically studied probiotic and nutritional products sold primarily DTC via subscription. The site identifies flagship products such as DS-01(R) Daily Synbiotic and new formulations (DM-02, AM-02, PM-02) and highlights science-led R+D (SeedLabs), global shipping, and sustainability initiatives. Seed positions itself as translating microbiome research into consumer-facing formulations, backed by clinical trials, partnerships with academic researchers, and a public-facing science education program (SeedUniversity). The company uses subscription and global fulfillment channels and lists social outbound links (Instagram, Twitter, LinkedIn) and a care email for inquiries.

1. On-site brand shown as 'Seed' and legal name 'Seed Health, Inc.' in site footer.
2. Flagship product DS-01(R) Daily Synbiotic and additional supplement SKUs (DM-02, AM-02, PM-02) sold via subscription DTC.
3. Public emphasis on clinical research, SeedLabs environmental R+D, and global shipping/fulfillment capabilities.
4. Contact methods and support channels published on-site (care@seed.com; help.seed.com) and social links to Instagram, Twitter, LinkedIn.

Seed is framed as a science-first microbiome company that commercializes research-backed consumer supplements and funds environmental microbial R+D through SeedLabs.

• DS-01(R) Daily Synbiotic: capsule-in-capsule probiotic formulation delivering 24 live strains to the colon; clinically studied and sold by subscription.
• DM-02(TM) Daily Multivitamin: new daily multivitamin SKU positioned to cover nutrient gaps and sold via subscription.
• AM-02(TM) Energy + Focus: daytime formulation for energy and focus sold as part of product lineup.
• PM-02(TM) Sleep + Restore: evening formulation to support sleep and restoration sold as part of product lineup.

Position Seed Health as a co-packing and contract-packaging partner experienced with dietary supplements, subscription fulfillment, and regulated consumer health products; emphasize expertise in handling capsules, multi-SKU subscription packaging, and cold-chain or temperature-stable probiotic logistics. Highlight certifications and regulatory support for supplement manufacturing and serialization.

A packaging provider could support Seed by scaling capsule filling, secondary packaging for subscription kits, and modular fulfillment integrations to support global shipping and return logistics. Value-adds include assistance with FDA-compliant labeling, lot traceability/serialization, temperature-resilient shipping qualification, and sustainability-driven material sourcing (PCR content, recyclable mailers). Potential challenges are managing live microbial stability requirements, validation of heat/transport resilience, and adherence to clinical batch record traceability. Fast-turnaround co-packing with quality systems (SQF/GMP) and proven DTC kitting will align closely with Seed's subscription-first model.

United States packaging market estimated in the low hundreds of billions USD annually (reports cite roughly USD 200-210+ billion range for 2025). (industry sources).

Recent market reports commonly project mid-single-digit CAGRs for US/North America packaging (approx. 3-5% CAGR depending on report) and 2-6% globally for packaging segments; next-generation and sustainable packaging segments show higher CAGR (approx. 6%+).

• Sustainable and recyclable materials demand (PCR, mono-materials) and regulatory pressure on recycled-content mandates.
• Growth of DTC and subscription e-commerce driving demand for protective, mail-optimized secondary packaging and automated kitting.
• Flexible packaging and next-generation formats gaining share due to cost and logistics efficiency; smart/traceable packaging and serialization rising in regulated segments.

Seed is co-founded and co-led by Ara Katz and Raja Dhir (Co-Founders, Co-CEOs), per multiple press and directory sources.

Not available

Press releases and media coverage in 2024-2025 note executive hires (Chief Medical Officer appointment), commercial launches (CODA computational biology platform referenced), and public interviews about profitability and R+D investments. No verified public revenue figures found on-site.

Prospect details are not publicly visible.